BostonGene provides AI-based molecular and immune profiling through its BostonGene Tumor Portrait™ Tests, which analyze tumor genomics, the tumor microenvironment, and host immunity to recommend therapies. Its integrated model combines genetics, transcriptomics, microenvironment, and tumor composition to give physicians a 360° overview of each tumor. Many academic and community oncologists across the United States have already adopted BostonGene’s Molecular Portrait Test to improve patient care. The company plans to use new capital to scale growth, continue innovation, expand clinical and research partnerships, and pursue international expansion. Leveraging NEC’s infrastructure, BostonGene and NEC intend to form a joint venture to bring solutions to patients in Japan and other Asian countries. The company is headquartered in Waltham, Mass. BostonGene develops a cloud-native biomedical software platform that combines genome and transcriptome sequencing, algorithms to estimate immune fitness and cancer characteristics, and a continuously updated expert-curated AI-driven database. The platform produces molecular profiles and delivers a patient-prioritized list of optimal immuno- and targeted therapy combinations based on tumor and tumor-microenvironment analysis. BostonGene emphasizes a holistic approach to defining optimal therapy combinations for individual patients, with particular focus on immuno- and targeted therapies. Founded in 2015, the company has evaluated its solution using extensive data in collaboration with leading U.S. cancer centers and maintains a robust intellectual property portfolio. The company recently secured financing to accelerate product development, collaborations, and team growth. Its stated mission is to enable physicians to provide each patient the highest probability of survival through personalized treatments.

Total raised

$200M

Funding rounds

2

Latest round

Series B

Latest activity

Apr 2022